Literature DB >> 24518091

Failure patterns relative to radiation treatment fields for stage II-IV thymoma.

Andreas Rimner1, Daniel R Gomez, Abraham J Wu, Weiji Shi, Ellen D Yorke, Andre L Moreira, David Rice, Ritsuko Komaki, Kenneth E Rosenzweig, Gregory J Riely, James Huang.   

Abstract

INTRODUCTION: The optimal radiation therapy (RT) field design for thymomas remains unclear. Here we report the failure patterns in stage II-IV thymoma after RT at two tertiary referral centers, classified according to the new International Thymic Malignancy Interest Group definitions.
METHODS: We reviewed 156 stage II-IV patients with thymoma treated with definitive (n=24) or adjuvant (n=132) RT. All RT was delivered without elective nodal irradiation (median dose 5040 cGy). Intrathoracic failures were classified as (1) in-field failures (within 100% isodose line [IDL]), (2) marginal recurrences (<100% and ≥50% IDL), and (3) out-of-field failures (outside the 50% IDL).
RESULTS: The median follow-up was 61 months. Surgical margins were positive in 39%. The median tumor size was 9 cm. The 5-year cumulative incidence of all intrathoracic failures was 24% (n=34). Failures occurred within the RT field (n=5), marginally (n=1), out-of-field (n=22), and synchronously in- and out-of-field (n=6). The 5-year cumulative incidence of in-field failures was 7%. These were associated with Masaoka stage and tumor size. Macroscopically positive margins were associated with more local failures. Intrathoracic failures occurred most commonly in the pleural space (n=29) and lymph nodes (n=9). Patients with more advanced stage, and those treated with intensity-modulated radiation therapy had more intrathoracic failures. RT dose and chemotherapy did not impact failure patterns.
CONCLUSIONS: Although there were few in-field failures in patients who received RT for stage II-IV thymomas, a high rate of out-of-field intrathoracic failures still occurred. Further study is necessary to identify treatment approaches that prevent pleural recurrences.

Entities:  

Mesh:

Year:  2014        PMID: 24518091     DOI: 10.1097/JTO.0000000000000099

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  12 in total

Review 1.  Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Authors:  Suchit H Patel; Andreas Rimner; Roger B Cohen
Journal:  Transl Lung Cancer Res       Date:  2017-04

2.  Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma-An Analysis of the International Thymic Malignancies Interest Group Retrospective Database.

Authors:  Andreas Rimner; Xiaopan Yao; James Huang; Alberto Antonicelli; Usman Ahmad; Robert J Korst; Frank Detterbeck; Daniel R Gomez
Journal:  J Thorac Oncol       Date:  2016-06-23       Impact factor: 15.609

3.  Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Authors:  Andreas Rimner; Daniel E Spratt; Marjorie G Zauderer; Kenneth E Rosenzweig; Abraham J Wu; Amanda Foster; Ellen D Yorke; Prasad Adusumilli; Valerie W Rusch; Lee M Krug
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-26       Impact factor: 7.038

Review 4.  The expanding role of radiation therapy for thymic malignancies.

Authors:  Jonas Willmann; Andreas Rimner
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 5.  Combining immunotherapy with radiation therapy in thoracic oncology.

Authors:  Shahed N Badiyan; Michael C Roach; Michael D Chuong; Stephanie R Rice; Nasarachi E Onyeuku; Jill Remick; Srinivas Chilukuri; Erica Glass; Pranshu Mohindra; Charles B Simone
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  The role of salvage radiotherapy in recurrent thymoma.

Authors:  Andrew Jihoon Yang; Seo Hee Choi; Hwa Kyung Byun; Hyun Ju Kim; Chang Geol Lee; Jaeho Cho
Journal:  Radiat Oncol J       Date:  2019-09-30

7.  Surgical feasibility and long-term outcome of superior vena cava replacement for advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy.

Authors:  Zhen Yu; Lei Yu; Tao Yu; Xing-Guo Yang; Bao-Xun Zhang; Xin Du
Journal:  Thorac Cancer       Date:  2021-02-10       Impact factor: 3.500

8.  Local radiotherapy for pleural dissemination of thymic tumors after initial treatment.

Authors:  Dai Okazaki; Yuta Shibamoto; Takeshi Yanagi; Satoshi Ishikura; Takuhito Kondo; Yuki Yamada; Masanari Niwa
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

9.  Radiotherapy for stage IVa thymoma-Shanghai Chest experience.

Authors:  Changlu Wang; Lanting Gao; Wentao Fang
Journal:  Mediastinum       Date:  2019-03-04

10.  Case presentation and recommendations from the April 2018 ITMIG tumor board: an international multidisciplinary team.

Authors:  Samantha S Sigurdson; Anja C Roden; Edith M Marom; Frank C Detterbeck; Conrad B Falkson
Journal:  Mediastinum       Date:  2019-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.